Multidisciplinary Care Ensures ‘Comfort’ in Decisions Surrounding Lumpectomy for Breast Cancer Subtype, Says Expert

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota, details the multidisciplinary work that goes into delivering breast-conserving therapy for patients with multiple ipsilateral breast cancer.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Judy C. Boughey, MD, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about the collaborative, multidisciplinary considerations that go into breast-conserving therapy for patients with multiple ipsilateral breast cancer.

According to Boughey, patients receiving breast conservation therapy will get the full value of a multidisciplinary team including breast surgeons, radiation oncologists, and medical oncologists.

Transcript:

All of breast cancer care these days is very much multidisciplinary. For these patients with multiple ipsilateral breast cancer, it does bring the value of a multidisciplinary team’s input into that patient's care. If the patient chooses to proceed with breast-conserving therapy, that's going to involve not only surgical resection, but also the incorporation of adjuvant whole breast radiation.

We want to make sure that the patient and the radiation oncologists are comfortable proceeding with the radiation aspects, and then also to incorporate the medical oncologist in terms of the systemic therapy recommendations.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Related Content